BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 14734229)

  • 1. A novel t(6;7)(p24;q21) in a chronic myelocytic leukemia in complete cytogenetic remission after therapy with imatinib mesylate.
    Gozzetti A; Tozzuoli D; Crupi R; Fanelli A; Gentili S; Bocchia M; Mazzotta S; Raspadori D; Lauria F
    Cancer Genet Cytogenet; 2004 Jan; 148(2):152-4. PubMed ID: 14734229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergence of Ph negative clones in chronic myeloid leukemia (CML) patients in complete cytogenetic remission after therapy with imatinib mesylate (STI).
    Gozzetti A; Tozzuoli D; Crupi R; Gentili S; Bocchia M; Raspadori D; Lauria F
    Eur J Haematol; 2003 Oct; 71(4):313-4. PubMed ID: 12950245
    [No Abstract]   [Full Text] [Related]  

  • 3. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience.
    Braziel RM; Launder TM; Druker BJ; Olson SB; Magenis RE; Mauro MJ; Sawyers CL; Paquette RL; O'Dwyer ME
    Blood; 2002 Jul; 100(2):435-41. PubMed ID: 12091333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
    Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate.
    O'Dwyer ME; Gatter KM; Loriaux M; Druker BJ; Olson SB; Magenis RE; Lawce H; Mauro MJ; Maziarz RT; Braziel RM
    Leukemia; 2003 Mar; 17(3):481-7. PubMed ID: 12646934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clonal chromosome aberrations in Philadelphia-negative cells from chronic myelocytic leukemia patients treated with imatinib mesylate: report of two cases.
    Herens C; Baron F; Croisiau C; Tassin F; Bours V
    Cancer Genet Cytogenet; 2003 Nov; 147(1):78-80. PubMed ID: 14580776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority.
    Bumm T; Müller C; Al-Ali HK; Krohn K; Shepherd P; Schmidt E; Leiblein S; Franke C; Hennig E; Friedrich T; Krahl R; Niederwieser D; Deininger MW
    Blood; 2003 Mar; 101(5):1941-9. PubMed ID: 12411298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular analysis of the Imatinib-induced complete cytogenetic response in chronic myelogenous leukemia.
    Miglino M; Grasso R; Varaldo R; Fugazza G; Colombo N; Clavio M; Canepa L; Garuti A; Ibatici A; Pierri I; Ballerini F; Sessarego M; Gobbi M
    Leuk Lymphoma; 2006 Jul; 47(7):1348-51. PubMed ID: 16923567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Presence of complex t(6;9;22;15) four-way chromosome rearrangement plus rare t(1;6) translocation with favorable response to imatinib therapy in chronic myelogenous leukemia.
    Lu CM; Zhou L; Feng S; Kohn PH; Qi Z; Yu J
    Leuk Lymphoma; 2011 Nov; 52(11):2182-4. PubMed ID: 21718138
    [No Abstract]   [Full Text] [Related]  

  • 10. Development and progression of a Philadelphia-chromosome-negative acute myelocytic leukemia clone in a patient with Philadelphia-chromosome-positive chronic myelocytic leukemia.
    Cullen MJ; Richards SJ; Dickinson H; Carter C; Swirsky DM; Owen RG
    Cancer Genet Cytogenet; 2004 Jan; 148(2):170-3. PubMed ID: 14734234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate.
    Matsuda M; Morita Y; Shimada T; Miyatake J; Hirase C; Tanaka M; Tatsumi Y; Maeda Y; Kanamaru A
    Int J Hematol; 2005 May; 81(4):307-9. PubMed ID: 15914360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of T-cell clonality in a patient with Ph-negative acute lymphocytic leukemia occurring after interferon and imatinib therapy for Ph-positive chronic myeloid leukemia.
    Wang L; Zhu K; Zha X; Chen S; Yang L; Chen S; Li Y
    J Hematol Oncol; 2010 Apr; 3():14. PubMed ID: 20377918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Disease transformation in imatinib mesylate treated Philadelphia chromosome-positive chronic myelogenous leukemia patients achieved cytogenetic remissions].
    Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Lu DP
    Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Dec; 37(6):612-5. PubMed ID: 16378113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.
    Wang L; Pearson K; Pillitteri L; Ferguson JE; Clark RE
    Br J Haematol; 2002 Sep; 118(3):771-7. PubMed ID: 12181044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose modification of imatinib by monitoring the level of BCR-ABL transcript in chronic myelogenous leukemia.
    Ishikawa I; Kato C; Harigae H; Sugawara T; Tomiya Y; Yamada M; Ishizawa K; Kameoka J; Miyamura K; Sasaki T
    Tohoku J Exp Med; 2006 Dec; 210(4):355-63. PubMed ID: 17146202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration.
    Campbell LJ; Patsouris C; Rayeroux KC; Somana K; Januszewicz EH; Szer J
    Cancer Genet Cytogenet; 2002 Nov; 139(1):30-3. PubMed ID: 12547154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the cytogenetic and molecular analyses in the assessment of imatinib response in chronic myelocytic leukemia.
    Palanduz S; Bayrak A; Sirma S; Vural B; Cefle K; Ucur A; Ozturk S; Yenerel MN; Besisik SK; Yavuz S; Diz-Kucukkaya R; Sargin D; Nalcaci M; Pekcelen Y; Ozbek U
    Genet Test Mol Biomarkers; 2009 Oct; 13(5):599-602. PubMed ID: 19814615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
    Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A chronic myeloid leukemia case with a variant translocation t(11;22) (q23;q11.2): masked Philadelphia or simple variant translocation?
    Acar K; Uz B
    Pan Afr Med J; 2018; 30():161. PubMed ID: 30455790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.